Table 1.
Descriptive Characteristics for N=312 FES PET scans in N= 239 patients
| N total (N=312 if blank) | N with characteristic (% of N) | Mean (SD) | Range | |
|---|---|---|---|---|
| Patient Characteristics | ||||
| Age (years) | 54 (12) | 23 – 88 | ||
| Female sex | 298 (96%) | |||
| Pre-menopausal (female only) | 298 | 98 (33%) | ||
| Advanced stage breast cancer† | 298 (96%) | |||
| HER2 positive primary tumor | 293 | 62 (21%) | ||
| Any FES negative sites | 311 | 80 (26%) | ||
| Weight (kg) | 74 (17) | 46 – 156 | ||
| BMI (kg/m2) | 27 (6) | 18 – 55 | ||
| Prior Treatment | ||||
| Prior chemotherapy | 298 | 220 (74%) | ||
| Prior radiation | 297 | 170 (57%) | ||
| Prior tamoxifen | 301 | 155 (51%) | ||
| Currently undergoing chemotherapy | 306 | 50 (16%) | ||
| Blood Assays | ||||
| Serum Estradiol (pg/mL) | 309 | 21 (43) | 0 – 567 | |
| Testosterone (ng/mL) | ||||
| men | 12 | 3.8 (2.8) | 0 – 9.0 | |
| women* | 284 | 0.3 (0.7) | 0 – 9.7 | |
| Albumin (g/dL) | 280 | 3.6 (0.4) | 2.3 – 5.1 | |
| Serum SHBG (nM) | 284 | 55 (37) | 3 – 287 | |
| FES metabolism (%at 20 min)** | 278 | 29 (13) | 4 – 83 | |
| FES Characteristics for Imaging | ||||
| FES specific activity at injection (GBq/mMol) | 267 | 156,917 (228,068) | 7992–1,671,216 | |
| FES injected Activity dose (MBq) | 185.0 (25.9) | 103.6 – 296 | ||
| FES injected per patient weight (nmol/kg) | 267 | 0.05 (0.05) | 0.001 – 0.31 | |
| SHBG Binding (%FES bound to SHBG) | 293 | 32 (15) | 0 – 66 |
†
Advanced Stage Breast cancer refers to Stage III or IV.
*
8% (23/284) of women had testosterone levels >0.7ng/mL
**
Percent of total blood activity present as FES at 20 minutes after injection determined by HPLC